# Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

> **NCT01439282** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 77 (actual)

## Conditions studied

- Estrogen Receptor Positive Tumor
- Breast Cancer

## Interventions

- **DRUG:** eribulin mesylate
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT01439282
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-11
- **Final completion:** 2014-05
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439282, "Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01439282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*